Mr Ned Brown

KANDO id: 40121

Bio

Ned focuses on the Life Sciences sector and is a member of the Health Evolution Partners Growth Fund’s Investment Committee. Ned has served public and private company board of directors, including current roles at Angiotech Pharmaceuticals and Cardiovascular Systems, and past roles at Tandem Diabetes and Novasom (formerly Sleep Solutions). Ned began working for HEP in 2010 as a Senior Advisor, and joined the firm full time in January of 2011. Ned has more than 25 years of experience in the healthcare industry, as an investor, board member and financial/strategic advisor. Past investment experience includes control buyouts of Charles River Labs and Wilson Greatbatch, growth equity investments in NxStage Medical and Prometheus Laboratories, and venture investments in Access Closure, Animas, Cardiovascular Systems(formerly Replidyne), Embolic Protection, Novasom, Spinal Concepts and Tandem Diabetes. Bachelor’s degree, Phi Beta Kappa, Magna Cum Laude, with High Honors, in English. Literatrure, Middlebury College. Winner of the Reid L. Carr Prize in English. Masters of Philosophy Program, Lincoln College, Oxford University. MBA, Anderson Graduate School of Management, UCLA.

Education